Evolution of the average Target Price on GILEAD SCIENCES, INC. |
|
|
Target Price consensus revisions : last 18 months |
|
|
Recommendations (Chart) GILEAD SCIENCES, INC. |
|
|
Analyst Recommendations on GILEAD SCIENCES, INC. |
|
|
| |
|
|
GSK to buy Sierra Oncology amid pressure to boost drug pipeline |
|
Mean consensus |
OUTPERFORM |
Number of Analysts |
27 |
Last Close Price |
63,18 $ |
Average target price |
70,07 $ |
Spread / Average Target |
10,9% |
High Price Target |
90,00 $ |
Spread / Highest target |
42,5% |
Low Price Target |
56,00 $ |
Spread / Lowest Target |
-11,4% |
Consensus revision (last 18 months)
|